Unfortunately, the severe injuries that Xarelto is linked to can lead to death. Many of the patients who took Xarelto and consequently experienced a severe internal bleeding event often die. The family of the deceased may have a right to file a wrongful death lawsuit against the drug and its manufacturers.
Wrongful Death Lawsuits
At this time, there have been several wrongful death lawsuits against Xarelto. These wrongful death lawsuits are filed by the closest living spouse/family of the deceased and usually seek compensation for:
- medical expenses that occurred during the treatment of the deceased
- funeral and burial expenses
- loss of wage earnings and financial support while the deceased was in treatment and of course future earning losses due to their death
Deaths Linked To Xarelto
Since Xarelto was approved, several studies have been released showing the link between Xarelto and serious side effects, mainly uncontrollable internal bleeding, that can cause death.
In 2013, the FDA worked with a company that specialized in analyzing adverse medical events to release a report on the adverse events of Xarelto. The study analyzed over 2,100 reports of adverse events regarding the blood thinner. 1,821 of these cases cited Xarelto as the main cause of the adverse event they experienced. The top four side effects that are linked to Xarelto include pulmonary embolism, deep vein thrombosis, gastrointestinal bleeds, and hemorrhages. Some of these conditions can be very difficult to detect until they pose a serious health threat, and for this reason unfortunately 891 of the cases in this study required hospitalization and 183 cases resulted in the death of the patient.
In January of 2015, Baylor College of Medicine in Texas performed a study funded by Bayer Healthcare and Janssen. The results of the study claimed that there was a risk of serious bleeding associated with Xarelto. The study noted that the results of this study were similar to the clinical studies that were referenced in Xarelto’s approval. The study analyzed the health of 27,467 of the patients who were taking Xarelto (Rivaroxaban) between January 2013 and March 2014. The study found that out of these patients, 478 individuals suffered from a major bleeding event and 14 individuals taking Xarelto died from the internal bleeding. The study was published in the Journal of Clinical Cardiology.
The doctors at Erasmus MC University Medical Center in Rotterdam, The Netherlands also performed a study on blood thinners in the same class as Xarelto, including Xarelto itself and Pradaxa. The goal of the study was to analyze the risk of gastrointestinal bleeds while taking these new blood thinners compared to the standard anticoagulants such as Warfarin. In the case of Xarelto, the doctors found that its usage carried an increased risk of internal bleeding almost 1.5 times higher than Warfarin carried. These researchers analyzed many blood thinners during this study and were very troubled by the fact that the drugs in the Xa inhibitor class, including Xarelto, lacked an antidote.